weekly_roundup

BioTechSign Daily Catalyst Roundup - November 05, 2026

Top BioTechSign catalyst names today: EYPT, SMMT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 5, 2026

Daily Biotech Catalyst Digest: November 05, 2026

EYPT leads the current BioTechSign screen at 84.8/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.84.8Aclinical activity 100%, short interest 70%, dilution risk 43%
SMMTSummit Therapeutics Inc.75.1BPDUFA timing 100%, publication signal 100%, clinical activity 100%
GRFSGrifols SA74.8Bpublication signal 100%, clinical activity 100%, dilution risk 19%
NKTRNektar Therapeutics74.0Bshort interest 90%, clinical activity 75%, dilution risk 65%
ARGXargenx SE74.0Bpublication signal 100%, clinical activity 100%, dilution risk 15%
NUVBNuvation Bio73.4Bclinical activity 88%, PDUFA timing 75%, short interest 70%

Recent Grade-Change Queue

  • URGN (UroGen Pharma Ltd.) currently grades F with a 27.8/100 catalyst score. Main inputs: clinical activity 54%, short interest 50%, dilution risk 45%.
  • FATE (Fate Therapeutics) currently grades F with a 25.5/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 35%.
  • COGT (Cogent Biosciences) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 88%, short interest 50%.
  • ANRO (Alto Neuroscience, Inc.) currently grades D with a 47.4/100 catalyst score. Main inputs: short interest 70%, clinical activity 50%, dilution risk 31%.
  • STOK (Stoke Therapeutics) currently grades F with a 26.9/100 catalyst score. Main inputs: short interest 70%, clinical activity 38%, dilution risk 28%.
  • NUVB (Nuvation Bio) currently grades B with a 73.4/100 catalyst score. Main inputs: clinical activity 88%, PDUFA timing 75%, short interest 70%.
  • TOI (The Oncology Institute, Inc.) currently grades D with a 40.9/100 catalyst score. Main inputs: publication signal 100%, dilution risk 65%, clinical activity 33%.
  • GENB (Generate Biomedicines, Inc.) currently grades D with a 42.5/100 catalyst score. Main inputs: clinical activity 67%, short interest 50%, dilution risk 44%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.